

PHARMACEUTICAL 2022



Vaxxinity Inc. Rank 277 of 466







PHARMACEUTICAL 2022



Vaxxinity Inc. Rank 277 of 466

The relative strengths and weaknesses of Vaxxinity Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vaxxinity Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 31% points. The greatest weakness of Vaxxinity Inc. is the variable Net Income, reducing the Economic Capital Ratio by 67% points.

The company's Economic Capital Ratio, given in the ranking table, is 82%, being 4.2% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	154,129
Cost of Goods Sold	1,937
Intangible Assets	0
Liabilities, Current	27,494
Liabilities, Non-Current	237
Other Assets	371
Other Compr. Net Income	0
Other Expenses	12,100
Other Liabilities	10,323
Other Net Income	0
Other Revenues	66
Property and Equipment	12,173
Research and Development	71,379
Selling, General and Administrative Expense	51,825

Output Variable	Value in 1000 USD
Assets	166,673
Liabilities	38,054
Expenses	137,241
Revenues	66
Stockholders Equity	128,619
Net Income	-137,175
Comprehensive Net Income	-137,175
Economic Capital Ratio	82%

